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ABSTRACT 
Alzheimer’s disease (AD) is a scourge of longevity that will drain enormous resources from 
public health budgets in the future. Currently, there is no diagnostic biomarker and/or 
treatment for this most common form of dementia in humans. AD can be of early familial-
onset or sporadic with a late-onset. Apart from the two main hallmarks, amyloid-beta and 
neurofibrillary tangles, inflammation is a characteristic feature of AD neuropathology. 
Inflammation may be caused by a local central nervous system insult and/or by peripheral 
infections. Numerous microorganisms are suspected in AD brains ranging from bacteria 
(mainly oral and non-oral Treponema species), viruses (Herpes simplex type I) and yeasts 
(Candida species). A causal relationship between periodontal pathogens/non-oral Treponema 
species of bacteria has been proposed via the amyloid-beta and inflammatory links. 
Periodontitis constitutes a peripheral oral infection that can provide the brain with intact 
bacteria and virulence factors and inflammatory mediators due to daily, transient 
bacteraemias. If and when genetic risk factors meet environmental risk factors in the brain, 
disease is expressed, in which neurocognition may be impacted, leading to the development of 
dementia. To achieve the goal of finding a diagnostic biomarker and possible prophylactic 
treatment for AD, there is an initial need to solve the etiological puzzle contributing to its 
pathogenesis. This review therefore addresses oral infection as the plausible aetiology of late 
onset AD (LOAD).  
___________________________________________________________________________ 
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Alzheimer’s disease (AD) is a neurodegenerative disease and the most common example of a 
group of diseases that manifest as dementia. It is associated with atrophy and specific 
neuronal death particularly in the hippocampal region of the brain (1).  Research into AD 
pathogenesis, has flagged two main categories of the disease: the familial onset presentation 
accounts for around 2% of all AD cases and the sporadic form of late-onset AD also referred 
to as LOAD constitutes approximately 98% of the cases. LOAD displays genetic 
susceptibility traits of which the well-known risk factor is inheritance of the apolipoprotein 
(APOEɛ4) gene allele (2) and, appears to require an environmental factor for disease 
expression. For example a pathogen-host interaction can exacerbate neurocognition in some 
elderly individuals who if in their 80+ years likely become diagnosed with LOAD (3, 4). The 
rationale for this review therefore is to try to explain the aetiology in the vast proportion of 
LOAD cases that relies upon common risk factors. Several scientists have proposed, one of 
these to be peripheral infections (5-11), and the accompanying systemic and local 
inflammatory mediators (11-13). Of these, the plausible risk from oral infection is the main 
focus of this review. 
   
PREVALENCE OF AD 
AD is a burden of longevity resulting from the superior quality of health care provision for all. 
This factor is likely to contribute to quadrupling of AD subjects living in our society during 
the next 40 years (14). It is estimated that by 2050 about 13-14 million people are likely to 
suffer from AD in the USA with a rise in the total costs estimated to be more than $1 trillion. 
The odds of having a diagnosis of AD when over 85 years of age exceed 1:3 (15). One in six 
people over 80 years in the UK has dementia (16). Estimates for the prevalence of AD in the 
USA indicate that more than 5 million individuals who are 65 years or older currently suffer 
from AD (1, 15). About 200,000 subjects have been diagnosed with the early-onset familial 
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AD form and health care costs for this disease are about $200 billion per year (1). It is clear 
that AD is fast becoming a major health challenge in the USA and around the globe that will 
financially drain public health budgets and care giver services. 
 
NEUROPATHOLOGICAL CHARACTERISTICS OF THE AD BRAIN 
The AD brain is characterized by several neuropathological features of which two seminal 
hallmarks (Fig. 1) arise from proteostasis of the ongoing neurodegenerative processes and are 
essential for a definitive diagnosis of the disease post mortem (17). One of the hallmark 
proteins is made up of fibrils in the form of extracellular, insoluble plaques and consists 
primarily of amyloid-beta (Aβ) (18). These peptide deposits in variable sizes depend upon the 
secretase enzymes (α-, β- and ϒ-secretases) that cleave it from the longer amyloid precursor 
protein (APP). Initial reports suggested fibrillar Aβ to be neurotoxic (19) as it has been shown 
to kill all types of cells by apoptosis induction (20). However, there are two known insoluble 
fibrillar Aβ amyloid peptides comprised of Aβ40 and Aβ42 amino-acid residues which exhibit 
distinct physiological states within the human brain. There is a general consensus among 
scientists that the larger (Aβ42) peptide is the neurotoxic form as the ageing brain of cognitive 
intact individuals also displays Aβ plaques. However, in the cognitively intact brain they are 
fewer in number and usually of the diffuse Aβ40 type that appears not to bear any, as yet 
known, pathological significance. In addition there are the soluble monomeric, dimeric and 
the multimeric forms of Aβ (21). The relative neurotoxicity of these isoforms remains unclear 
(22).  
More recently, the fibrillary forms of the Aβ(40/42) peptides released in the AD brain were also 
recognized as “defensin” or innate immune defense molecules that act to protect the host 
against infection (23). For example, both of the aforementioned amyloidogenic peptides can 
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bind to bacterial membranes and in that way lyse bacterial cells. Although Aβ is acting as an 
antimicrobial peptide (AMP), it may be a part of the brain’s ancient/modern innate immune 
defense mechanism. AMPs are potent, broad-spectrum, pore-forming agents targeting Gram-
negative and Gram-positive bacteria, enveloped viruses and protozoans (23), thereby 
supporting the hypothesis that AD has an infectious origin.  
 
Furthermore, the senile plaques (Aβ42) are recognized as triggers that stimulate activation of 
microglial cells and initiate local immune responses (24). Activated microglia are the most 
important contributors of inflammation in the central nervous system (CNS) (25). They 
secrete a number of proinflammatory cytokines (24-26) and recognize pattern associated 
molecular patterns (PAMPs) on bacteria and their cellular debris (27-30) in response to CNS 
infection.  
The other pathological characteristic of AD is an accumulation of intracellular 
hyperphosphorylated tau and heat shock proteins constituting the neurofibrillary tangles 
(NFTs). Hyperphosphorylated tau protein alters the polymerization and stability of 
microtubules compromising their function (31). NFTs in AD reflect the severity of disease; 
however, the significance of pathogen-host interaction to the occurrence of NFTs in the AD 
brain is poorly understood. Current genetic evidence is pointing to aberrant innate immune 
responses (32, 33) and cholesterol lipid genes (34) having greater significance in AD 
pathogenesis. A dysfunctional immune system and predisposition to hyperlipidaemia also 
support the role of reduced blood flow due to the vascular lesions and inflammation, Aβ 
deposition and microorganisms in AD.   
In advanced AD pathology, synaptic dysfunction is another structural defect associated with a 
decline in memory (35-37). Although a circular argument, malnutrition plays a role in the 
gradual loss of synapses and fewer teeth during life is a known risk factor for AD (38). 
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Neurons are capable of responding to injury by expressing multiple neurotransmitters. In AD, 
selective loss of cholinergic neurons in the basal forebrain (39) also correlates with the loss of 
cognitive function (18, 35).  
 
THE AMYLOID CASCADE HYPOTHESIS  
Several hypotheses have been advanced regarding the development of AD. The amyloid 
cascade hypothesis serves as a model particularly for the familial form of AD (40) which is a 
disease caused by mutations involving the amyloid- protein precursor, located on 
chromosome 21 and presenilin 1 and 2 on chromosomes 14 and 1 respectively that enhance 
the APP gene processing towards Aβ deposition (41, 42). The model, which was first 
proposed by Glenner and Wong (43), maintains that the neurodegenerative disease is due to 
an imbalance between the generation and clearance of Aβ. Genome wide association studies 
(GWAS) highlighted the complement receptor 1 (CR1) gene playing a role in AD 
pathogenesis (44). One recognized role of CR1, a membrane bound regulatory protein, is its 
ability to bind C3b opsonins (Fig. 2). It is abundantly expressed especially on erythrocyte 
membranes and as such participates in immune complex clearance by transporting waste to 
the liver and the spleen. As the CR1 gene is a risk factor for LOAD, this suggests loss of 
function as a possibility for the defective clearance of Aβ in the brain. Other tentative 
explanations suggest variation in CR1 protein isoforms (longer and shorter forms) (45), 
whereby the longer form is less involved in the disease process via its ability to bind more 
C3b and facilitate more effective clearance of Aβ in the brain (46). This is a process that 
inevitably fails favoring disease expression with more Aβ proteostasis buildup and 
complement pathway activation. The amyloid hypothesis has been modified several times, 
particularly due to the finding that soluble oligomers of Aβ may contribute to early preclinical 
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stages of the disease that initiate the cascade leading to synaptic dysfunction, atrophy and 
neuronal loss (47).  
 
THE INFLAMMATORY HYPOTHESIS  
The intrinsic model 
Currently there are two models of the inflammatory hypothesis of AD, an intrinsic and an 
extrinsic. The intrinsic inflammation model accounts for the intact “blood-brain barrier” 
(BBB) restricting entry of neurotoxic immune molecules and systemic lymphocytes to the 
brain.  As a consequence, the brain glial cells are able to generate a local and complete innate 
immune system when challenged by foreign agents (26, 48-50). Historically, 
neuroinflammation has largely been viewed as being a downstream consequence of the 
amyloid hypothesis, whereby the presence of amyloidogenic peptides result in the activation 
of microglia initiating pro-inflammatory cascades and the release of potentially neurotoxic 
substances resulting in degenerative changes in neurons. GWAS now implicates innate 
immune genes (44, 51) as being a risk factor and supports a primary role for the inflammatory 
elements of AD pathology via inappropriate activation of the complement system (52-54) in 
association with Aβ plaques and NFTs (55).  
 
The extrinsic model 
The extrinsic model accounts for communication of the glial cells with the immune challenges 
presented via the blood vascular system using the circumventricular organs and the choroid 
plexus that are devoid of the BBB (56). The cells from this region of the brain are fully 
equipped with the CD14 receptor and the toll-like receptor 4 (TLR 4) to recognize LPS from 
the peripheral blood circulation (27, 28). Hence, elements of systemic infections such as those 
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originating from Gram-negative, highly virulent oral pathogens, bronchopneumonia and 
urinary tract infections (3, 4, 7, 57, 58) reach all organs including the CNS.  Bacterial 
products entering the bloodstream trigger the  innate immune responses of host cells via 
pattern recognition receptors (PPR) and TLRs   that alert local and distant cells to the 
infectious threat by secreting immune mediators (cytokines) to confine and defeat the foreign 
agents. Increased risk of dementia in the elderly following multiple infectious episodes has 
been reported (4). In addition, systemic infections appear to contribute towards delirium in 
some clinically diagnosed AD patients and such episodes can exacerbate a premorbid 
cognitive status (3). Holmes et al. proposed that since cytokines are primary mediators 
released by the host to defend against infection, such secondary stimuli (IL-1β and TNF-α) 
may mediate their effect on the brain and indirectly contribute to cognitive decline (3, 57).  
 
NON-ORAL BACTERIA RELATED TO AD 
Honjo et al. (59) using Bradford Hill’s criteria for assessing the relationship between bacteria 
and disease found Chlamydophila pneumoniae to be a likely infectious agent related to the 
pathogenesis of AD. Maheshwari and Eslick (60) reported a strong correlation between C. 
pneumoniae and AD, and according to Shima et al. (61) C. pneumoniae is currently the most 
plausible of all infectious agents proposed to be involved in AD. Lim et al. (62) suggested that 
the pro- and chronic inflammatory states in AD pathogenesis may in part be due to C. 
pneumoniae infection of monocytes. C. pneumoniae antibodies from typical intracellular and 
atypical C. pneumoniae antigens have been identified both in the frontal and temporal cortices 
of brains from AD patients (63). Amyloid deposit and NFTs were detected in the same 
regions in apposition to one another suggesting that C. pneumoniae infection is involved in 
the development of AD pathology. 
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Using various techniques Balin et al. (9) found C. pneumoniae in 80-90% of LOAD brain 
tissue specimens. C. pneumoniae infection was correlated with the APOEɛ4 allele expression. 
The same researchers subsequently demonstrated that astroglia, microglia, neurons, 
endothelial cells and monocytes in the LOAD brain are permissive to this bacterium. The 
mechanisms of pathogenesis differ between actively- and persistently-infecting chlamydiae 
and it is in the persistent state that these organisms cause chronic disease (64, 65). C. 
pneumoniae was cultured from two AD brain samples after one or two passages in HEp-2 
cells (66). Interestingly, the study indicated that brain isolates were more related to respiratory 
than to vascular/atheroma strains of C. pneumoniae. This suggested that C. pneumoniae 
infection of the brain was secondary to bronchopneumonia and at the end stages of LOAD. 
It has been suggested that the phages phiCPAR39 and phiCPG1, associated with C. 
pneumoniae, may enter mitochondria of the bacterial host and work as slow viruses initiating 
AD (67). These authors hypothesized that mitochondrial recruitment by C. pneumoniae 
phages may be the primary initiating event in the pathogenesis of neurodegenerative 
disorders. 
In a meta-analysis based on 25 relevant, primarily case-control studies Maheshwari and Eslick 
(60) found a statistically significant association between AD and detectable evidence of 
infection caused by C. pneumoniae or spirochetes. They reported over a ten-fold increased 
occurrence of AD when there was evidence of spirochetal infection (OR: 10.61; 95% CI: 
3.38-33.29) and over a four-fold increased occurrence of AD with a conservative risk estimate 
(OR: 4.45; 95% CI: 2.33-8.52). There was a five-fold increase in occurrence of AD with C. 
pneumoniae infection (OR: 5.66; 95% CI: 1.83-17.51). Accordingly, a strongly positive 
association between bacterial infection and AD was shown for both types of bacteria, but it 
was strongest for spirochetes. 
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It is generally accepted that the syphilis spirochete Treponema pallidum can cause chronic 
neuropsychiatric disorders including dementia as well as other neurodegenerative disorders 
(11). T. pallidum causes brain atrophy and Aβ deposition in the atrophic form of general 
paresis (68, 69) and is a strong indication for involvement of spirochetes in AD pathogenesis. 
Chronic diseases such as syphilis are frequently associated with deposition of amyloid (68, 
69). Amyloid is an integral component of spirochetes which may contribute to amyloid 
deposition in AD (70).  Spirochete accumulation in the cerebral cortex in the context of 
syphilis will also lead to formation of senile plaques, NFTs and granulovacuolar degeneration 
(71).  
Miklossy (68, 69) analyzed data on the ability of spirochetes to induce pathological and 
biological hallmarks of AD in vitro following Koch’s and Hill’s postulates and demonstrated 
a plausible causal relationship between neurospirochetosis and AD. The data revealed a 
statistically significant association between spirochetes and AD (P = 1.5 x 1017, OR = 20, 
95% CI = 8-60, N = 247).  When mammalian cells were exposed to spirochetes, the 
pathological and biological hallmarks of AD were reproduced in vitro (68, 69).  Historical 
observations supported the conclusion that chronic spirochetal infections can cause dementia 
and reproduce the neuropathological hallmarks of AD (72). According to Miklossy (72), these 
observations represent further evidence in support of a causal relationship between various 
spirochetal infections and AD. 
Another spirochete also implicated in AD is Borrelia burgdorferi, the causative agent of 
Lyme disease which is transfected to humans via tick vectors . There are great similarities in 
the clinical and pathological manifestations of syphilis and Lyme disease (72, 73). The 
occurrence of B. burgdorferi in the brains of AD patients was first reported by MacDonald 
and Miranda (74) and was confirmed later by MacDonald (75, 76), Riviere et al. (5) and 
Miklossy et al. (77). Interestingly, Bu et al. (78) found that the infectious burden consisting of 
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B. burgdorferi, C. pneumoniae, Helicobacter pylori, cytomegalovirus and Herpes simplex-1 
(HSV-1) is associated with AD. In contrast, Gutacker et al. (79) and Pappolla et al. (80) found 
no evidence for an association between B. burgdorferi and AD. 
Among other bacterial species, H. pylori (monoinfection) has been found to be related to AD 
(59). These authors suggested that AD pathology can be initiated and exacerbated by some 
microorganisms with inflammatory and oxidative responses which may affect the brain 
continuously and gradually over time. However, the H. pylori status was not associated with 
AD in a study from Japan, probably due to the high prevalence of the organism in controls 
(81). This was refuted by Kountouras et al. (82) who had previously found that successful 
eradication of  H. pylori infection was associated with significantly lower mortality risk in AD 
patients [HR (95% Cl)=0.287 (0.114-0.725), p=0.008] (83). 
 
ORAL BACTERIA RELATED TO AD 
The oral cavity harbors an impressive range of bacterial phylotypes (84). Molecular 
identification methods have detected close to 900 different predominant bacterial species of 
which 35% cannot yet be cultured (85). The oral microbiome profiles appear to be 
individualized (86), meaning that bacterial microbiomes can vary both qualitatively and 
quantitatively between individuals, although there are also significant overlaps. Each 
individual can  harbor up to 200 different bacterial taxa in their mouth and there is a large 
variation in the microbiota in different oral sites (84, 87). Furthermore, the composition of the 
oral microbiota irrespective of being indigenous or pathogenic in the oral cavity keeps 
changing in view of major oral diseases (caries, gingivitis, aggressive and chronic 
periodontitis, periodontal-endodontic lesions, peri-implantitis and mucositis) (88-94). 
Particularly plaque-induced oral diseases such as periodontitis are associated with a change in 
12 
 
the oral microbiota. There is a predominance of anaerobic bacteria in the oral cavity. Many of 
the major periodontal microorganisms are anaerobic, e.g., Porphyromonas gingivalis, 
Treponema denticola and Tannerella forsythia. The abundance of anaerobes tend to increase 
with the development of plaque-induced oral diseases.  
 
Periodontal bacterial pathogens are related to AD 
Major pathogens of chronic periodontitis such as P. gingivalis, T. forsythia and T. denticola 
are implicated in the development of several inflammatory diseases at remote organ sites. 
Except for T. forsythia, all three of the above-named organisms of which T. denticola  
represents a spirochete, have been found in the AD brain (5, 8). Spirochetes are strongly 
neurotropic. They can spread along nerve fibers and via lymphatics (67, 68) and have been 
detected in the trigeminal nerve and trigeminal ganglia (95). Spirochetes and their antigens as 
well as DNA have been found associated with AD and are strongly implicated as the 
causative agents leading to dementia (68, 69). In 14 studies spirochetes were detected in AD 
by different authors in different laboratories and countries by means of different techniques 
(for reviews see Miklossy (68, 69). Riviere et al. (5) demonstrated the presence of seven 
different oral Treponema species in 14 out of 16 AD brain specimens (Fig. 3). Spirochetes 
were even cultivated from the brains of AD patients indicating that they were viable in the 
brain (67, 68, 77). Miklossy suggested a co-infection by several spirochetes in AD including 
the oral varieties (T. socranskii, T. pectinovorum, T. denticola, T. medium, T. amylovorum and 
T. maltophilum) as demonstrated by Riviere et al. (5). Spirochetes reproduced the biological 
and pathological hallmarks of AD after exposure of mammalian neuronal and glial cells in 
organotypic cultures (68, 69). 
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It  was demonstrated that LPS from periodontal bacteria can access the AD brain during life 
while detection in corresponding controls, with equivalent or longer postmortem interval was 
absent (8). This study supports the literature on elevated antibodies to periodontal disease-
associated bacteria such as P. gingivalis, being found in AD patients (7). Furthermore, in 
2,355 people 60 years and over, the third NHANES study found associations between 
periodontitis and cognitive impairment and between measures of immunoglobulin to P. 
gingivalis and cognitive test performance (96, 97). In this study all participants were 
cognitively intact at baseline. Those who went on to develop AD had higher levels of serum 
antibodies to periodontal pathogens at baseline. The study  suggested a temporal relationship 
in that the periodontal disease came before AD.   
Other important periodontal pathogens related to AD are Fusobacterium nucleatum and 
Prevotella intermedia. In the NHANES study antibody levels to these organisms were 
significantly increased (α = 0.05) at baseline serum in patients with AD compared to controls 
(97). The results were significant after controlling for baseline age, Mini-Mental State 
Examination score, and allele APOEɛ4 status. Noble et al. (98) found that a high anti-
Actinomyces naeslundii titer (> 640 ng/ml, present in 10% of the subjects) was associated 
with increased risk of AD (HR = 2.0, 95% CI: 1.1-3.8). This association was stronger after 
adjusting for other significant titers (HR = 3.1, 95%CI: 1.5-6.4) and confirmed that periodontal 
pathogens may be associated with AD. 
 
Possible consequences to the brain carrying oral bacterial pathogens  
The fact that inflammation is sustained in the AD brain suggests that local immunogenic 
hallmark proteins and/or peripheral infections are key perpetrators. This is supported by 
reports highlighting microorganisms and their toxic products as well as DNA in brain tissue 
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of AD patients and experimental animals (see  below). Bacteria activate pathways that include 
the integrin receptor CR3 (CD11b/CD18) and TLR signalling (99) and the complement 
cascade (100). The NF-κB signalling pathway for cyto/chemokine release (TNF-α, IL-8) 
(101) produces free radicals, nitric oxide triggers and apoptosis (102). The oral cavity, lungs 
and gastrointestinal and urinary tracts are plausible sources of brain microorganisms. The 
likely passage of the microorganisms of interest from their original sites to the brain is 
described below. 
Infections with spirochetes can cause cerebral hypoperfusion (103), cerebrovascular lesions 
and a severely disturbed capillary network (68, 69).  Chronic spirochetal infections can also 
induce slowly progressive dementia, cortical atrophy, chronic inflammation and Aβ 
deposition,  indistinguishable from that occurring in AD brains (for reviews see 68, 69, 72). 
Furthermore, cultured neuronal cells exposed to spirochetes produce Aβ (104). Spirochetes 
are also able to form plaque-, tangle- and curly fiber-like lesions (72, 105). They induce a 
latent and slowly progressive infection by evading host defenses. This promotes their 
survivial and proliferation in the brain by blocking the complement cascade. Spirochetes may 
even survive and proliferate in hosts that are immune-competent. Interestingly, the remarkable 
ability of T. pallidum to evade clearance from the immune system has earned it the 
designation “stealth pathogen” (106). The activated complement cascade following spirochete 
infections (11) may be used as a non-specific marker of CNS inflammation. Spirochete-host 
interactions initiate and sustain chronic inflammation triggering various immune responses 
that activate the innate and adaptive immune system, free radical production, apoptosis and 
amyloid deposition typically seen in AD brains (107).  
P. gingivalis has been designated as one of the “keystone” periodontal pathogens because it is 
able to establish and maintain the periodontal disease-associated “inflammophillic” 
microbiota (108). It is able to perform this task as it possesses an awesome variety of 
15 
 
virulence factors, recently reviewed by Singhrao et al. (109), to evade the host immune 
defenses, thus serving two major functions: initial survival of P. gingivalis itself via a 
sustainable inflammatory milieu and  sustainment of nutritional sources by eliminating 
microbial competitors (108).  
The P. gingivalis endotoxin LPS demonstrates differences in the number of phosphate groups 
together with both the amount of lipid A fatty acids and their specific position. The presence 
of multiple lipid A structures makes it more difficult for the innate host responses to  
recognize the molecule thereby aiding the virulence of P. gingivalis (110). The consequences 
of finding P. gingivalis LPS in the host’s body, e.g. the brain (8), include priming of immune 
cells for differential activation of the TLR-mediated NF-κB signalling pathway (111) leading 
to cytokine liberation, complement activation and maintenance of intracerebral inflammation. 
P. gingivalis evades circulating phagocytes by adhering to erythrocytes (112). An active 
invasion of P. gingivalis and infection-induced complement activation with bystander neural 
injury was detected in the brains of ApoE-/- mice (113). This supported previous notions that 
bacterial infections can contribute to the development of AD pathology via mechanisms 
involving acute phase proteins such as cytokines and the complement cascade where neurons 
would be attacked.  
 
ORAL VIRUS RELATED TO AD 
Herpes simplex virus (HSV) is present in more than 70% of the population after 50 years age 
(114-116). It persists latently in the peripheral nervous system and is periodically reactivated. 
Characteristically, HSV-1 has been designated as the enemy within (10). Herpes viruses, 
including Epstein-Barr virus and cytomegalovirus, are found in high copy counts in 
aggressive periodontitis, and may interact synergistically with periodontopathic bacteria in the 
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pathogenesis of this disease (117). Periodontal infections activated by Herpes virus may 
impair local host defenses and thus increase the aggressiveness of resident periodontopathic 
bacteria. The bacteria, in turn, may augment the virulence of the herpes viruses.  
High proportions of viral-associated proteins in amyloid-containing plaques and/or NFTs 
corroborate with the involvement of HSV-1 in AD pathology (118). Notably, De Chiara et al. 
(119)  reported an association between Aβ accumulation in the brain and HSV infection. 
Itzhaki et al. (120) suggested that not only does HSV-1 produce the main components of 
amyloid plaques and NFTs (i.e. Aβ and hyperphosphorylated tau), but it also interferes with 
the autophagic events that prevent degradation of these proteins and eventually leading to 
their accumulation in the AD brain.  Further, in vitro and in vivo investigations  in murine 
models following HSV-1 infections  demonstrated Aβ accumulation (121).  
A number of scientists have suggested that there is imbalance between production and 
clearance of β-amyloid in the brain, a premise first proposed by Wisniewski et al. (122) based 
on the discovery of soluble species of this protein and later confirmed by Zlokovic et al. 
(123).  It is now widely accepted that defective clearance of this protein is  a hallmark of AD 
brains  leading to its accumulation in the form of insoluble Aβ40/42 plaques. Although HSV 
and cytomegalovirus have been detected in the brains of older adults with and without AD 
(124-126), HSV-1 viral DNA is present in a higher proportion of AD patients (127). It is 
particularly seen in the temporal and frontal cortices which are the brain regions that are most 
damaged in AD (128, 129). The relevance of this association is still under investigation; 
however a plausible role for the HSV-1 viral DNA could be associated with the plaque 
maturation process. Jamieson et al. (127) found that the virus was absent from the brains of 
most young people, probably because it enters the brain during old age either  with immune  
senescence (130) or the virus itself is initially responsible for weakening the host’s immune 
defenses. This latter explanation is likely and is supported by us and others (131).  
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HSV-1 is a strong risk factor for AD in the brains of those with the APOEɛ4 allele (125, 132). 
This virus is not only a dormant passenger but can persist in the latent form in neurons or 
replicate at a very low level in neuroglia (133). During persistence it may release toxic 
products continuously and induce pro-inflammatory cytokines at low levels which become an 
additional burden to a host already challenged by age, poor diet, restricted exercise as well as 
any genetic susceptibilities. Itzaki and Wozniak (10) suggested that stress or peripheral 
infection can reactivate the virus periodically from latency in the brain. This may cause an 
acute but presumably localized infection, and subsequent damage modulated by the APOɛ 
gene can lead to formation of Aβ plaques and NFTs. 
The presence of anti-HSV IgM, a sign of reactivated infection, almost doubled the risk for AD 
while anti-HSV IgG did not influence the risk (134). Kobayashi et al. (135) suggested that the 
anti-HSV-1 Ig antibody avidity index could be a useful biomarker for early diagnosis of 
anamnestic mild cognitive impairment, which is prodromal to AD, as well as for AD 
sufferers. 
Reactivation of HSV seropositivity is highly correlated with incident-AD (136). Letenneur et 
al. (136) speculated that AD pathology starts many years before frank dementia and recurrent 
reactivation of HSV can act as a potent stimulus to brain microglia, increasing cytokine 
levels, and triggering a positive feedback cycle leading to increasing accumulation of 
neurohistopathological changes. In other words, infection, followed by local CNS 
inflammatory reaction is the likely primary stimulus wheras proteostasis is a consequence of 
the primary event leading to the development of AD. 
Hill et al. (137) suggested a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 
from the complement system which is a major first-line host defense mechanism, and the 
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activation of key elements in the arachidonic acid cascade known to contribute to AD-type 
neuropathological changes. 
 
ORAL YEASTS RELATED TO AD 
Oral yeast infection represents a secondary opportunistic infection  particularly involving 
Candida albicans, but increasingly non-albicans species, e.g. Candida glabrata. With a 
growing population of elderly, severe systemic fungal infections have increased dramatically 
in this age group during the last 30 years (138, 139). Oral yeasts can be found in periodontal 
pockets, in root canals, on the mucosae and underneath dentures (denture stomatitis) (140-
142). Denture stomatitis is prevalent in elderly wearing dentures that are heavily contaminated 
with yeasts which can be a source of systemic mycosis. Disseminated mycoses have recently 
been reported in AD patients (143, 144). Fungal molecules including proteins and 
polysaccharides [(1,3)-β-glucan] were detected in peripheral blood serum, and fungal proteins 
and DNA were demonstrated by PCR in brain tissue of AD patients. Chitin-like fungal 
structures have also been found in the AD brain (145) and chitinase activity has been 
proposed as a powerful biomarker of AD (146).  In AD brains, cytoplasmic material in a 
small number of  cells  was targeted by antibodies with immunoreactivity to yeast cells (147). 
These findings were consistent with the idea that neurons can be infected by fungi. 
Interestingly, antifungal treatment reversed the clinical symptoms of some AD patients (148, 
149). 
 
HOW DO ORAL MICROORGANISMS REACH THE BRAIN? 
Blood stream dissemination 
19 
 
The most likely pathway for dissemination of oral microorganisms to the brain is through the 
blood stream (150). Dental treatment as well as brushing, flossing, chewing and use of tooth 
picks in a patient with periodontitis will release a bacteraemia (151). This can occur several 
times during the day and has been estimated to last for up to 3 hours for oral bacteria (152). 
The bacteraemia is usually  contained by immune cells of the body. However, in people with 
reduced immune defense, e.g. older individuals, bacteria may  localize to crevices of the oral 
cavity and vascular channels (150).  
The blood- brain barrier 
An intact blood-brain barrier (BBB) prevents microorganisms in the blood from accessing the 
brain. However, aging favors overgrowth of oral microorganisms, particularly anaerobic 
bacteria and facultative yeasts that established earlier in life and provoked pro-inflammatory 
responses that weakened the BBB (16). Notably, magnetic resonance imaging (MRI) 
confirmed loss of BBB integrity in a mouse model of disseminated candidosis (153). Loss of 
integrity allows microorganisms to spread through the blood stream and quietly contribute in 
the pathogenesis of AD. During immunosenescence, the innate immune system gradually 
takes over for the acquired immune system. This contributes to a rise in circulating 
proinflammatory cytokines such as TNF-α (16).  Indeed, proinflammatory mediators can 
cross the BBB (3, 7, 154). APOEɛ4, TNF-α  and perhaps Ephrin Type-A Receptor 1 (EphA1) 
may influence BBB integrity and thus be important for penetration of bacteria, LPS and other 
toxic bacterial products as well as yeasts into the brains of AD patients (16).  APOEɛ4 affects 
the integrity of the BBB by activating the cyclophilin A matrix metalloproteinase MM-9 
pathway (155). 
 It is also plausible to suggest that the permeability of the BBB increases with age and thus 
promotes AD pathogenesis making the brain accessible to microorganisms. Mice with a 
mutation in the amyloid precursor protein gene which is related to early-onset AD in man, 
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showed increased permeability of the BBB and increased formation of senile plaque as 
compared to control mice (156). The changes increased with age.  
 
Circumventricular organs and perivascular spaces 
Circumventricular organs (permit polypeptide hypothalamic hormones to leave the brain 
without disrupting the BBB) are not dependent on the BBB (56) and may act as another entry 
portal to the brain for bacteria (157).  Poole et al. (8) postulated that bacteria and their 
products may also directly access the brain via the systemic circulation through the 
perivascular spaces.  
     
The olfactory hypothesis 
The “olfactory hypothesis” suggests the olfactory tract as a potential route for pathogenic 
bacteria to enter the brain and thereby trigger the production of Aβ and NFTs (158). The 
olfactory and trigeminal nerves are known to be used by periodontal pathogens to bypass the 
BBB for direct passage to the CNS (5, 150, 159, 160). Identification of oral treponemes in the 
trigeminal ganglia supports such a route of dissemination (5). Further, spirochetes may spread 
along the fila olfactoria and tractus olfactorius (68, 69).  
Olfactory unsheathing cells (OECs) engulf bacteria and migrate towards TNF-α released by 
activated astrocytes (161). Therefore, OECs could be a vehicle for transporting live bacteria to 
the brain (i.e., Trojan horse). The olfactory bulb was the first area where NFTs and Aβ 
deposition were detected in the neuropathological trajectory of AD in humans (162) and in 
mouse models of AD (163). 
 
21 
 
GENETIC, NUTRITIONAL AND ENVIRONMENTAL FACTORS PROMOTING AD 
While early-onset AD is genetically determined, LOAD is thought to result from interaction 
between genetic and environmental factors (12). Several mutated genes are associated with 
the familial AD, such as the amyloid beta (Aβ) precursor protein (AβPP) gene and the 
presenelin-1 (PSEN-1) and PSEN-2 gene (164-166). A major risk factor for LOAD is 
polymorphism in the APOɛ4 allele (2). Also cytokine-related genes seem to be involved in the 
susceptibility to inflammation in both LOAD (167, 168) and periodontitis (169-171). Thus, 
polymorphisms that increase TNF-α also increase the risk of both AD and periodontitis (172, 
173). Lambert et al. (174) found that 20 different loci can increase host susceptibility to AD 
including polymorphisms in genes associated with interleukin-1 (IL-1) (71, 175-178) and 
TNFα (71, 172, 179-181). The APOɛ4 gene which is one of these 20 loci is highly correlated 
with AD (182) but it is also a risk factor for infection and increases the expression of 
inflammatory mediators (11). Recently, genetic overlap between AD, C-reactive protein 
(CRP) and plasma lipids was demonstrated by using summary statistics from GWAS of over 
200,000 individuals (183). There may also be interplay between genetic risk and 
environmental risk factors such as toxins and or bacterial, viral and fungal pathogens in 
LOAD reflecting its complex and multifactorial etiology (1). 
Diet with its content of essential B-vitamins, phospholipids and other micronutrients are 
important for forming new nerve synapses (184). Nutritional deficiencies are common both in 
elderly and in dementia subjects as briefly discussed by Singhrao et al. (150). 
 
ASSOCIATION BETWEEN CHRONIC PERIODONTAL DISEASE AND AD 
There is increasing evidence for an association between chronic periodontitis and LOAD 
(185). Cross-sectional and longitudinal studies have demonstrated that gingival bleeding, loss 
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of periodontal attachment, periodontal probing depth, alveolar bone loss and antibodies to 
periodontal pathogens are significantly associated with lower cognitive function and decline 
after adjustment for co-variates (for a review see (12)). Acute phase proteins, including 
cytokines are possible indirect links between periodontal pathogens and/or their virulence 
factors (12, 13). Elderly often show neglect of oral hygiene which can stimulate recurrent 
chronic oral infection (150). This again promotes inflammation which can lead to confusion 
and dementia (3, 4, 154). In 152 subjects 50-70 years of age who were followed for 20 years, 
greater levels of periodontal inflammation correlated with lower cognitive levels (186). 
Furthermore, gingival bleeding and loss of periodontal attachment were significantly 
associated with cognitive impairment in a cohort of 5,138 people aged 20-59 years (187). In 
144 nuns, those encoding APOEɛ4 and who had fewer teeth experienced more rapid cognitive 
decline than those with neither or either of these risk factors (188). Clinical and 
epidemiological studies showed that loss of teeth is associated with poor memory (6, 96, 187, 
189). In another study of 597 community dwelling men followed for 32 years, tooth loss, 
increasing periodontal pocket depths and progression of alveolar bone loss were associated 
with impaired cognition particularly in those over 45 years of age (190). Recently, de Souza 
Rolim et al. (191) found that periodontal infections were more frequent in patients with mild 
AD than in healthy subjects. Another interesting feature related to the pathogenesis of AD is 
the low level of infection by “commensals on the loose” (16). These “immuno-tolerated” 
bacteria may silently multiply in sites outside of their primary niche and an ongoing infection 
at their secondary location may have significant deleterious effects upon the health of the 
elderly or demented host with an existing immunocompromised status.  
 
PUTATIVE TREATMENT AND PROPHYLAXIS OF AD 
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There is no effective treatment or prophylaxis yet for AD, but several approaches have been 
proposed. Efforts in this respect are important. If we could delay onset of dementia by only 2 
years we might lower the prevalence of AD by more than 22 million cases over the next 40 
years (14). Notably, the inheritance of the APOEɛ4 allele in the very old (90+) age group, 
appears to confer protection (192), having bypassed a period of being at risk around 85+ years 
of age. 
If periodontal disease is implicated in AD, periodontitis prophylaxis  could be of help. It 
would be interesting to see if this has any effect on the initiation and aggravation of AD but 
an observation period of decennia is probably needed. 
In a study of subjects with mild to moderate AD, a 3-month course of doxycycline and 
rifampicin reduced cognitive deterioration during a 6 months’ follow-up interval  (193). It 
was concluded that use of antibacterial compounds may not have had any effect on the 
treatment of C. pneumoniae but had a beneficial effect on cognitive decline in AD (193). This 
might be related to prevention or attenuation of a number of peripheral infections or 
dampening down the proinflammatory cytokine response. Minocycline was found to correct 
early, pre-plaque neuroinflammation and inhibit the APP cleaving enzyme 1 (BACE-1) in a 
transgenic model of Alzheimer's disease-like amyloid pathology (194). It was suggested that 
interfering with inflammation could be a useful therapeutic approach in early, pre-plaque 
stages of AD-like amyloid pathology. 
Anti-inflammatory drugs given for at least 2 years before the onset of dementia delayed the 
disease process (195-197). It may also be beneficial to combine anti-inflammatory agents with 
antibacterials (193). Examination of several available Non-steroidal Anti-Inflammatory Drugs 
(NSAIDs) showed that only a few of them had any useful Aβ-modifying or other activity of 
therapeutic use in LOAD (for a review see (1)).  
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Itzhaki and Wozniak (10, 198) suggested that antiviral therapy and perhaps vaccination 
against HSV-1 in early life could be useful. If HSV-1 is implicated in AD, vaccination could 
prevent the excessive accumulation of Aβ in the brain. Vaccination with mixed HSV 
glycoproteins prior to HSV infection protected against viral latency in mouse brains (199). 
Also Mori (200) maintained that antiviral approaches including chemotherapy and 
vaccination are promising for prevention and treatment of AD and remain to be validated. 
Furthermore, Carter (118) suggested that vaccination or antiviral agents and immune 
suppressants may be considered as therapeutic options before or during the early stages of 
AD. Interestingly, exposure of HSV-1-infected cell cultures to intravenous immunoglobulin 
acting via anti-β-amyloid antibodies reduced the accumulation of Aβ and phosphorylated tau 
(201).  
Angiotensin-converting enzyme (ACE) from Stigmatella aurantiaca may cleave the Aβ 
peptide similar to human ACE and may be used as a novel form of treatment against AD 
(202). Furthermore, Chiarini et al. (203) maintained that calcilytics could halt AD progression 
and preserve the patients' cortical neurons, cognitive abilities, and eventually life if given at 
minimal cognitive impairment or at earlier stages. Studies using mice suggested the use of tau 
aggregation inhibitors as potential drugs for the treatment of AD and other tauopathies (204).  
Resveratrol is a polyphenol present in red wine. Its capability of directly interfering with the 
toxic β-amyloid protein aggregation in AD has recently been shown (205). Resveratrol was 
found to reduce Aβ-induced toxicity in a Caenorhabditis elegans model of AD by targeting 
specific proteins involved in proteostasis and thereby reducing the amount of aggregated Aβ 
(206). This is in concert with our previous finding that the effect of a drinking pattern of 2-7 
times per week reduced the risk of myocardial infarction among men who had a history of 
tooth extractions due to periodontal/dental infection (207). 
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Potent inhibitors of Aβ oligomer formation or Aβ-induced cell toxicity have proven to be 
attractive means for therapeutic intervention of AD.  Song et al. (208) found that the anti-
Alzheimer effects of centipedegrass, which contains several C-glycosyl flavone constituents, 
occurred through inhibition of neuronal cell death by intervening with oligomeric Aβ 
formation and reducing beta-site amyloid precursor protein cleaving enzyme 1 activity. The 
authors suggested that Maysin, a major flavonoid of corn silk, in centipedegrass could be an 
excellent therapeutic candidate for the prevention of AD. 
Active immunization against important domains of Alzheimer tau eliminated tau aggregation 
and neurofibrillary pathology (209). The AD type of tau hyperphosphorylation was abolished 
in transgenic mice by vaccination across a wide range of AD phospho-epitopes. Kontsekova 
et al. (209) demonstrated that active immunization of rats with a tau peptide encompassing the 
epitope revealed by monoclonal antibody DC8E8 led to elimination of all major hallmarks of 
neurofibrillary pathology involving a 95% reduction in the AD-type hyperphosphorylation of 
tau. 
 
CONCLUSIONS 
LOAD which is the predominant form of AD, does not seem to have a single cause. On the 
contrary, a multitude of factors may be involved and they may act in concert. Among others 
both genetic and environmental factors may be involved. Even among microorganisms, 
cooperation may occur since the brain can hardly differentiate between different microbial 
insults which collectively contribute capacity for enhancing inflammation. Irrespective of the 
cause, systemic inflammation may predict the onset of dementia. Organisms such as 
spirochetes, P. gingivalis, C. pneumoniae, H. pylori, Herpes simplex type I virus and Candida 
are among the prime candidate pathogens  in AD brains. In the cascade of events causing AD, 
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oral microorganisms may play a role, particularly anaerobic bacteria such as treponemes, P. 
gingivalis, Prevotella spp., Fusobacterium and Actinomyces, but also facultative anaerobic 
Candida species. It is important to recognize that infection can occur decades before the 
manifestation of dementia. The most convincing evidence for a causal relationship between 
oral bacteria and AD is noted for spirochetes which are both neurotropic and motile. It is 
likely that oral infection can be a risk factor for Alzheimer’s disease but it is not the only one. 
Experiments in humans may require long exposure time to disclose key events and 
mechanisms of AD. There is, as yet, no cure for AD despite concerted efforts and investment 
by industry. Prevention of AD through long-term use of antibiotics may be impractical and 
could select for resistant bacteria. This is  worrisome as the prevalence of AD and the public 
expenses related to its management are expected to increase greatly in the next decade. If 
anaerobes of periodontitis have a major role in AD, dental hygiene and treatment will provide 
the AD prophylaxis from an early age as periodontitis is modifiable. However, improving oral 
hygiene and treating periodontal disease in the AD patient can be challenging since patients 
are often uncooperative. There is also need for training care-givers to assist with oral care in 
such patients.  
Vaccination against key organisms and important domains of AD has had some beneficial 
effect. Also several agents interfering directly with the pathogenesis of AD have been tested. 
In order to find a cure, there is a need for clinical diagnostic information and knowledge of 
the causal agents for AD so that specific treatment options targeting these organisms  can be 
developed. As for diagnostic biomarkers, increased antibody levels to specific oral pathogens 
in particular to P. gingivalis may be used as a monitoring tool years before clinical 
manifestation of AD. This is important because treatment will probably have to start early.  
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Figure legends 
 
Fig. 1. The pathological hallmarks of AD, numerous extracellular amyloid-Aβ plaques 
and intra-neuronal neurofibrillary tangles (NFTs). Although there are several NFTs, 
only one is picked out in boxes at x 10 and x 40 objective lens magnification. 
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Fig. 2. Immunofluorescence labelling (green dots) of hippocampal CA neurons 
opsonised by iC3b following monoinfection with P. gingivalis at 24 weeks of APOɛ 
gene knockout (ApoE−/−) mice. This is indirect evidence of an oral infection having 
affected the host’s brain. 
 
 
Fig. 3 Section of pons area of Alzheimer's disease brain from an 84-year-old female 
subject (from ref. 5 with permission), demonstrates metabolically active Treponema 
pectinovorum oral bacteria (arrows) stained dark blue following immunostaining with 
anti-T. pectinovorum  using the avidin-biotin peroxidase method. 
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